About J.
Mark Ray offers health care clients a nuanced and business-focused approach to public or private company M&A and corporate finance transactions. His knowledge of the unique regulations, risks, and market pressures affecting health care companies results in unique insights and creates value for his clients.Mark is the former chair of Alston & Bird’s Health Care Group, which includes teams of corporate, FDA, health policy, and health care compliance lawyers. He concentrates his practice primarily on complex public and private company mergers and acquisitions and corporate financing transactions for clients in the health care sector.While Mark is an experienced corporate transactional lawyer, he has developed additional proficiency in the unique laws, regulations, risks, and market pressures affecting health care companies. In particular, he is experienced in structuring public and private transactions and joint ventures to comply with the federal Stark Law, the anti-kickback laws, federal and state licensure requirements, and the corporate practice of medicine doctrine. When representing medical device and pharmaceutical companies, he applies an understanding of the intersection of FDA regulation, IP law, and health care regulatory issues affecting these companies. In addition to his transactional practice, Mark also advises clients on a broad range of legal issues, such as formation, securities law compliance, corporate governance, and fiduciary duties.
Mark Ray offers health care clients a nuanced and business-focused approach to public or private company M&A and corporate finance transactions. His knowledge of the unique regulations, risks, and market pressures affecting health care companies results in unique insights and creates value for his clients.Mark is the former chair of Alston & Bird’s Health Care Group, which includes teams of corporate, FDA, health policy, and health care compliance lawyers. He concentrates his practice primarily on complex public and private company mergers and acquisitions and corporate financing transactions for clients in the health care sector.While Mark is an experienced corporate transactional lawyer, he has developed additional proficiency in the unique laws, regulations, risks, and market pressures affecting health care companies. In particular, he is experienced in structuring public and private transactions and joint ventures to comply with the federal Stark Law, the anti-kickback laws, federal and state licensure requirements, and the corporate practice of medicine doctrine. When representing medical device and pharmaceutical companies, he applies an understanding of the intersection of FDA regulation, IP law, and health care regulatory issues affecting these companies. In addition to his transactional practice, Mark also advises clients on a broad range of legal issues, such as formation, securities law compliance, corporate governance, and fiduciary duties.
Mark Ray offers health care clients a nuanced and business-focused approach to public or private company M&A and corporate finance transactions. His knowledge of the unique regulations, risks, and market pressures affecting health care companies results in unique insights and creates value for his clients.
Mark is the former chair of Alston & Bird’s Health Care Group, which includes teams of corporate, FDA, health policy, and health care compliance lawyers. He concentrates his practice primarily on complex public and private company mergers and acquisitions and corporate financing transactions for clients in the health care sector.
While Mark is an experienced corporate transactional lawyer, he has developed additional proficiency in the unique laws, regulations, risks, and market pressures affecting health care companies. In particular, he is experienced in structuring public and private transactions and joint ventures to comply with the federal Stark Law, the anti-kickback laws, federal and state licensure requirements, and the corporate practice of medicine doctrine. When representing medical device and pharmaceutical companies, he applies an understanding of the intersection of FDA regulation, IP law, and health care regulatory issues affecting these companies. In addition to his transactional practice, Mark also advises clients on a broad range of legal issues, such as formation, securities law compliance, corporate governance, and fiduciary duties.
